RESUMO
AIM: The study was aimed at researching the specific wound healing activity of the drug with a comprehensive therapeutic effect based on derivatives of glucosamine and acrylic polymers to treat the infected wounds of various origins on a model of a planar infected wound. METHODS: The model of septic wounds in rats as per the method of P.I. Tolstykh was used during the study of the specific activity of the drug with a comprehensive therapeutic effect based on derivatives of glucosamine and acrylic polymers for the treatment of infected wounds. The infection was performed with the S. aureus and E. coli strains. The study lasted 18 days, and during this period no full scarring occurred. The wound diameter was chosen as the effectiveness criterion. The planimetric method was used to assess the course of the wound process in experimental animals. RESULTS: The obtained data prove the specific action of the drug with a comprehensive therapeutic action based on derivatives of glucosamine and acrylic polymers to treat the infected wounds of various origins. The study has shown that bacterially infected wounds healed worse than noninfected ones. Both types of wounds - infected and uninfected ones - healed faster when applying the test drug or Levomekol ointment. CONCLUSION: On the model of a planar infected wound, the developed drug with a comprehensive therapeutic action has shown better wound healing effect compared with the Levomekol reference drug.
RESUMO
BACKGROUND: Parkinson's disease is one of the most common neurological diseases. Pathogenesis of the disease is associated with destruction and death of neurons that produce the neurotransmitter dopamine. The precursor to dopamine, which crosses the protective blood-brain barrier, is the amino acid 3, 4-dihydroxy-L-phenylalanine - levodopa, L-DOPA. The investigational drug is a pharmaceutical composition, containing L-DOPA as an active substance, which is distributed in a polymer matrix based on a biodegradable copolymer of lactic/glycolic acids. AIM: This work aimed to study the main pharmacokinetic parameters for the drug "L-DOPA - PC, nasal drops" and comparator drugs "L-DOPA in oil", "L-DOPA - PC in purified water", reference product - tablets "Madopar 125". METHODS: To increase the bioavailability of the active substance L-DOPA, a new route of administration was used for the first time - nasal administration. Pharmacokinetics of the innovative drug with the intranasal route of administration was investigated in rabbits. The L-DOPA concentration in blood plasma was determined by high-performance liquid chromatography with tandem mass spectrometry (HPLC-MS/MS). RESULTS: Bioavailability of the drug - nasal drops were 244.4% compared with the drug "Madopar 125". CONCLUSION: Assay procedure for the determination of L-DOPA in animal blood plasma using liquid chromatography with tandem mass-selective detection (HPLC-MS/MS) was developed and validated.
